Showing 1 - 5 results of 5 for search 'Ju-Seog Lee', query time: 0.01s Refine Results
  1. 1
    Genomic Profiling of Liver Cancer

    Genomic Profiling of Liver Cancer by Ju-Seog Lee

    Published 2013-12-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”

    Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Tr... by Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

    Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbr... by Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Peng Wei, Ju-Seog Lee

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Comparative transcriptomes of adenocarcinomas and squamous cell carcinomas reveal molecular similarities that span classical anatomic boundaries.

    Comparative transcriptomes of adenocarcinomas and squamous cell carcinomas reveal molecular similarities that span classical anatomic boundaries. by Eric W Lin, Tatiana A Karakasheva, Dong-Jin Lee, Ju-Seog Lee, Qi Long, Adam J Bass, Kwok K Wong, Anil K Rustgi

    Published 2017-08-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]

    Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol... by Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: